Scarica l'app Stockscreener
12.67
1.02%
-0.13
Dopo l'orario di chiusura:
12.60
-0.07
-0.55%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.80
Aprire:
$12.82
Volume 24 ore:
993.73K
Relative Volume:
0.35
Capitalizzazione di mercato:
$1.64B
Reddito:
$628.25M
Utile/perdita netta:
$-78.55M
Rapporto P/E:
-20.44
EPS:
-0.62
Flusso di cassa netto:
$-29.73M
1 W Prestazione:
+7.74%
1M Prestazione:
+6.47%
6M Prestazione:
+73.32%
1 anno Prestazione:
-30.99%
Intervallo 1D:
$12.64
$13.05
Intervallo di 1 settimana:
$11.41
$13.05
Portata 52W:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Confronta NEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
12.67 | 1.66B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
617.15 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.57 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
714.55 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.81 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
244.29 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
A Look At NeoGenomics (NEO) Valuation After Recent Share Price Momentum Shift - Yahoo Finance
NeoGenomics, Inc. (NEO) Investor Outlook: Diagnostic Leader With 18% Upside Potential - DirectorsTalk Interviews
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The AI Journal
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
NeoGenomics Adds Diagnostics Executive Jack Kenny To Board - Pulse 2.0
HighMark Wealth Management LLC Has $3.09 Million Position in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Announces Board Changes to Support Future Growth - The Globe and Mail
NeoGenomics appoints diagnostics veteran Jack Kenny to board By Investing.com - Investing.com Nigeria
NeoGenomics, Inc. (NEO) Stock Analysis: Exploring a 13% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
NeoGenomics appoints diagnostics veteran Jack Kenny to board - Investing.com
Neogenomics appoints diagnostics and lab services industry veteran John P. "Jack" Kenny to its board of directors - MarketScreener
NeoGenomics Announces Board Changes - TradingView — Track All Markets
Neogenomics Appoints Diagnostics And Lab Services Industry Veteran John P. “Jack” Kenny To Its Board Of Directors - TradingView — Track All Markets
NeoGenomics, Inc. Announces Resignation of Dr. Alison L. Hannah as a Director, Effective December 31, 2025 - marketscreener.com
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors - The Joplin Globe
NeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, Florida - ACCESS Newswire
NeoGenomics, Inc. $NEO Shares Sold by Kopp Family Office LLC - MarketBeat
Does NeoGenomics (NASDAQ:NEO) Have A Healthy Balance Sheet? - 富途牛牛
Is NeoGenomics Inc. (NG9) stock a safe buy pre earnings2025 Earnings Surprises & Safe Swing Trade Setups - Улправда
Will NeoGenomics Inc. (NG9) stock outperform foreign stocks2025 Sector Review & Free Risk Controlled Daily Trade Plans - Bölüm Sonu Canavarı
How rising interest rates impact NeoGenomics Inc. stock2025 Price Momentum & Trade Opportunity Analysis - Улправда
Will NeoGenomics Inc. stock benefit from infrastructure spendingMarket Sentiment Report & Real-Time Market Trend Scan - DonanımHaber
Can NeoGenomics Inc. (NG9) stock sustain margin levelsCPI Data & Trade Opportunity Analysis Reports - Улправда
Should NeoGenomics’ Cleared RaDaR Patent Overhang and New Data Shift the NEO Investment Narrative? - Sahm
Will NeoGenomics Inc. stock continue dividend increasesJuly 2025 Gainers & Precise Swing Trade Entry Alerts - Улправда
Pathological Examination Market set to strong growth with a CAGR - openPR.com
Natera dismisses appeal in patent case against NeoGenomics By Investing.com - Investing.com Australia
Millennium Management LLC Acquires Additional Shares in NeoGenomics Inc - GuruFocus
Natera dismisses appeal in patent case against NeoGenomics - Investing.com India
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litig - pharmiweb.com
NeoGenomics Says Natera Withdraws Appeal in Patent Case - marketscreener.com
Neogenomics announces that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation - marketscreener.com
Neogenomics Announces That Natera Has Voluntarily Withdrawn Its Appeal In Ongoing RaDaR Patent Litigation - TradingView — Track All Markets
NeoGenomics, Inc. $NEO Shares Acquired by Squarepoint Ops LLC - MarketBeat
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation - Yahoo Finance
Value Recap: Will NeoGenomics Inc NG9 stock outperform foreign stocksJuly 2025 Retail & AI Enhanced Execution Alerts - moha.gov.vn
US Market Wrap: Why NeoGenomics Inc stock is trending among retail tradersJuly 2025 Summary & Safe Entry Point Identification - moha.gov.vn
Bellevue Group AG Reduces Stake in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Inc Stock Analysis and ForecastTake Profit Strategies & Start Your Free Trading Journey Today - earlytimes.in
What analysts say about The Hershey Company stockShort Interest Overview & Free Long-Term Investment Planning - earlytimes.in
The Supreme Industries Limited (SUPREMEIND) Announces Strategic ShiftValue Traps to Avoid & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Will New RaDaR MRD Data and Myeloid Profiling Advances Change NeoGenomics' (NEO) Diagnostics Narrative? - simplywall.st
NeoGenomics to Present New ctDNA Research at SABCS 2025 - BioSpace
NeoGenomics (NEO): Assessing Valuation After a 44% Three-Month Share Price Rebound - Yahoo Finance
Quantbot Technologies LP Buys New Holdings in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - BioSpace
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.56%
2.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):